Call for Abstract

19th International Vaccines & B2B Congress, will be organized around the theme “ A Global Discussion on technologies, advances and challenges in Vaccines”

Vaccines Congress 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vaccines Congress 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Egg-based Vaccine
  • Track 1-2Cell-based Vaccine
  • Track 1-3Clinical development of Vaccine
  • Track 1-4Development of Pandemic Vaccines
  • Track 1-5Quality control and assurance of Vaccines
  • Track 1-6Safety and Efficacy of attenuated vaccine
  • Track 1-7Biomarkers of Vaccine safety and efficacy
  • Track 2-1Vaccine delivery methods
  • Track 2-2Intradermal vaccine delivery system
  • Track 2-3Strategies for intranasal vaccine delivery
  • Track 2-4Oral vaccine delivery system
  • Track 2-5Vaccine delivery in developing countries
  • Track 2-6Conventional Vaccine delivery system
  • Track 2-7Vaccine delivery using viral vectors
  • Track 2-8Advances in Vaccine delivery
  • Track 3-1Organic adjuvants
  • Track 3-2Inorganic adjuvants
  • Track 3-3Immunologic adjuvants
  • Track 3-4Cytokines as adjuvants
  • Track 3-5Plant saponins as adjuvants
  • Track 3-6Liposomal adjuvants
  • Track 3-7Alum as an adjuvant
  • Track 3-8Mechanism of Action of adjuvants
  • Track 4-1Production of DNA Vaccines
  • Track 4-2Delivery of DNA Vaccines
  • Track 4-3Mechanism of Action of DNA Vaccine
  • Track 4-4Immune response of DNA Vaccine
  • Track 4-5Application of nucleic acid vaccines
  • Track 5-1Preventive cancer vaccine
  • Track 5-2Therapeutic Cancer Vaccine
  • Track 5-3Technologies related to cancer vaccine
  • Track 5-4Clinical trials of cancer vaccines
  • Track 5-5Researches on cancer vaccine
  • Track 6-1Development of HIV Vaccine
  • Track 6-2Future aspects of HIV Vaccine
  • Track 6-3Necessity of HPV vaccines and its doses
  • Track 6-4Limitation of HPV Vaccine
  • Track 6-5Hepatitis-B vaccine for liver cancer
  • Track 6-6Autologous tumor derived heat shock protein vaccine for liver cancer
  • Track 7-1Geriatric Immunization
  • Track 7-2Zoster vaccine
  • Track 7-3Flu shots for seniors
  • Track 7-4Risk factor in Geriatric immunization
  • Track 7-5Immunization schedule for elderly people
  • Track 8-1Canine Vaccination guideline
  • Track 8-2Feline Vaccination guideline
  • Track 8-3Other feline Vaccines
  • Track 8-4Vaccination guideline for animals
  • Track 8-5Core vaccines
  • Track 9-1Technology behind Plant Vaccines
  • Track 9-2Challenges of Plant Vaccines
  • Track 9-3Transgenic plants for immunotherapy
  • Track 9-4Vaccine from Tobacco plant
  • Track 9-5Rabies antigen from spinach
  • Track 9-6Edible plant vaccine
  • Track 9-7Plant Vaccines over Conventional Vaccines
  • Track 10-1Inactivated Vaccines
  • Track 10-2Live Virus Vaccines
  • Track 10-3Toxoid Vaccine
  • Track 10-4Subunit Vaccines
  • Track 10-5TB Vaccine
  • Track 10-6Influenza Vaccine
  • Track 11-1Standard immunization for children
  • Track 11-2Schedule of children vaccine
  • Track 11-3Routine Vaccinations
  • Track 11-4Polio Vaccine
  • Track 11-5Conjugate Vaccine
  • Track 12-1Diphtheria Vaccine
  • Track 12-2Vaccine for pneumonia
  • Track 12-3Anthrax Vaccine
  • Track 12-4Measles Vaccine
  • Track 12-5Tetanus Vaccine
  • Track 13-1Method of case study report
  • Track 13-2Case study report of Vaccine
  • Track 13-3Case study report of HPV vaccine
  • Track 13-4Case study report on Polio vaccine
  • Track 13-5Case study report on influenza vaccine
  • Track 13-6Case study on cervical cancer vaccine